

Listing of Claims:

- 1-22. (Canceled)
23. (Previously Presented) An adjuvant composition, comprising (A) an ionic polysaccharide and (B) an immunostimulating complex that comprises (i) a saponin and (ii) cholesterol, wherein the mass ratio of the ionic polysaccharide to the immunostimulating complex is in the range of 50 to 300.
24. (Previously Presented) The adjuvant composition of claim 23, wherein the ionic polysaccharide is an ionic dextran.
25. (Previously Presented) The adjuvant composition of claim 24, wherein the ionic dextran is DEAE-dextran.
26. (Previously Presented) The adjuvant composition of claim 23, wherein the immunostimulating complex is a protein-free immunostimulating complex.
27. (Previously Presented) The adjuvant composition of claim 23, wherein the immunostimulating complex further comprises a phospholipid, and wherein the saponin is Quil A.
28. (Previously Presented) The adjuvant composition of claim 23, wherein the mass ratio of ionic polysaccharide component to immunostimulating complex component is in the range of about 100 to about 140.
29. (Previously Presented) The adjuvant composition of claim 28, wherein the mass ratio is about 125.
30. (Previously Presented) The adjuvant composition of claim 23, comprising about 10 mg of the ionic polysaccharide and about 80 µg of the immunostimulating complex, wherein the ionic polysaccharide is DEAE-dextran.
31. (Previously Presented) The adjuvant composition of claim 23, comprising about 100 mg of the ionic polysaccharide and about 800 µg of the immunostimulating complex, wherein the ionic polysaccharide is DEAE-dextran.
32. (Previously Presented) An immunogenic composition comprising an immunogen and the adjuvant composition of claim 23.
33. (Previously Presented) The immunogenic composition of claim 32, wherein said immunogen comprises LHRH.
34. (Previously Presented) The immunogenic composition of claim 33, wherein said immunogen comprises an LHRH-diphtheria toxoid conjugate.

35. (Previously Presented) The immunogenic composition of claim 34, comprising from about 5 to about 500 µg of LHRH-diphtheria toxoid conjugate, from about 5 to about 500 mg of the ionic polysaccharide, and from about 40 to about 4000 µg of the immunostimulating complex.
36. (Previously Presented) A pharmaceutical composition, comprising (i) the immunogenic composition of claim 32, and (ii) one or more pharmaceutically acceptable carriers.
37. (Previously Presented) A method of eliciting an effective immune response in an animal, comprising administering to an animal an effective amount of the immunogenic composition of claim 32.
38. (Previously Presented) The method of claim 37, wherein said composition further comprises one or more pharmaceutically acceptable carriers.